StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lyell Immunopharma's price to sales ratio was 9.5× on Jan 31, 2024, against 20.8× a year earlier. Over the last 3 years it ranged from 6.0× to 445.5×, with a median of 28.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 20249.5×−0.6
2023Dec 29, 202310.1×−12.0
2022Dec 30, 202222.1×−160.9
2021Dec 31, 2021183.0×–

More Lyell Immunopharma figures

See a number that looks wrong?